Knight plans to market a range of over-the-counter and prescription products. The knowledge and experience of our principals has been focused on urology and endocrinology, but Knight intends to broaden the scope of its product pipeline beyond these disciplines.
Global (except US)
Treatment of visceral and cutaneous Leishmaniasis
Impavido® (miltefosine) is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. As an oral agent, it is registered in Germany, several countries in South America and the Indian subcontinent for the treatment of visceral and cutaneous leishmaniasis. Miltefosine was included in the WHO essential medicines list as an anti-leishmaniasis medicine in March 2011.
Canada (Option for Israel, Russia and Sub-Saharan Africa
Treatment of visceral, cutaneous, and mucosal Leishmaniasis
U.S. FDA approval received on March 19, 2014. Commercialization plan currently under development.
Knight will be seeking an initial indication for ATryn in Canada for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
ATryn (recombinant antithrombin) is administered in a hospital setting to patients with a known hereditary antithrombin deficiency to help patients avoid peri-operative and peri-partum thromboembolic events. It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients. ATryn received approval in the United States from the FDA in 2009 and marketing authorization by the European Commission prior to that in 2006. Additional clinical trials with ATryn are being conducted in pregnant women who suffer from severe preeclampsia to determine the possible benefits of ATryn to both the mother and her unborn child.
In Canada, PHOTOFRIN® is indicated for the treatment of esophageal cancer, endobronchial cancer, high-grade dysplasia in Barrett's esophagus and papillary bladder cancer.
Photodynamic therapy (PDT) with PHOTOFRIN (porfimer sodium) is a two-stage process requiring administration of both drug and a light source. PHOTOFRIN belongs to a group of cancer-fighting medications known as antineoplastics. It kills cancer cells by making them more sensitive to the destructive effects of a laser light, which is aimed at them after injecting the medication. This is why the procedure is called photodynamic therapy. Additional clinical trials with PHOTOFRIN are being conducted in patients with cholangiocarcinoma who are not candidates for surgery.